plinabulin (BPI 2358) / Jiangsu Hengrui Pharma, BeyondSpring  >>  Phase 2
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
plinabulin (BPI 2358) / BeyondSpring
NCT04345900: Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

Completed
2
55
US, RoW
Plinabulin, Pegfilgrastim, G-CSF
BeyondSpring Pharmaceuticals Inc.
Chemotherapy-induced Neutropenia
03/18
04/18
NCT04227990: Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

Completed
2
115
RoW
Plinabulin, Pegfilgrastim, Neulasta, Docetaxel, doxorubicin, and cyclophosphamide (TAC)
BeyondSpring Pharmaceuticals Inc.
Chemotherapy-induced Neutropenia
10/18
01/19
KeyPemls-004, NCT05599789: Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs

Recruiting
2
47
RoW
Pembrolizumab in Combination with Plinabulin and Docetaxel
Peking Union Medical College Hospital, BeyondSpring Pharmaceuticals Inc., Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer Metastatic
12/24
12/25
KeyPemls-005, NCT05745350: First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

Not yet recruiting
2
45
NA
Pembrolizumab, Plinabulin plus Etoposide and Platinum
Xiaorong Dong
Small Cell Lung Cancer Extensive Stage
05/25
12/25
NCT05130827: Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Checkmark Presentation of data in combination with pegfilgrastim for Multiple Myeloma Patients who have undergone AHCT
Aug 2022 - Aug 2022: Presentation of data in combination with pegfilgrastim for Multiple Myeloma Patients who have undergone AHCT
Active, not recruiting
2
17
US
Plinabulin
Memorial Sloan Kettering Cancer Center, BeyondSpring Pharmaceuticals Inc.
Multiple Myeloma
11/25
11/25
NCT00630110: Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
1/2
172
US, RoW
docetaxel, docetaxel (Taxotere), NPI-2358 + docetaxel, NPI-2358; docetaxel (Taxotere)
Nereus Pharmaceuticals, Inc.
Cancer
06/11
06/11
NCT02846792: Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Terminated
1/2
5
US
Nivolumab, Opdivo, Plinabulin, NPI-2358
University of Washington, National Cancer Institute (NCI)
ALK Gene Translocation, EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, ROS1 Gene Translocation, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
07/18
08/18
BTCRC-LUN17-127, NCT03575793: A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Checkmark Initial data from trial in combination with opdivo and yervoy for recurrent small cell lung cancer at ASCO 2021
Jun 2021 - Jun 2021: Initial data from trial in combination with opdivo and yervoy for recurrent small cell lung cancer at ASCO 2021
Checkmark Data from combination with nivolumab and ipilimumab for 2L & 3L SCLC
May 2021 - May 2021: Data from combination with nivolumab and ipilimumab for 2L & 3L SCLC
Checkmark From trial in combination with nivolumab and plinabulin for recurrent SCLC at ASCO 2021
More
Active, not recruiting
1/2
39
US
Nivolumab, Opdivo, Plinabulin, Ipilimumab, Yervoy
Salma Sabbour, BeyondSpring Pharmaceuticals Inc., Bristol-Myers Squibb, Rutgers Cancer Institute of New Jersey
Lung Cancer, SCLC
09/23
07/24
NCT04902040: Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Recruiting
1/2
12
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Plinabulin, NPI-2358, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
M.D. Anderson Cancer Center
Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Merkel Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
06/25
06/25

Download Options